Stasinos Chr. Sikalias · The science of compounding

Amiodarone 5 mg/mL oral suspension

CGR-US-003 · Nationwide Children’s Hospital — Pharmacy Services, institutional compounding formula

Institutional sourceCGR-US-003USA · institutional sources

INSTITUTIONAL SHEET — applies only to the exact described formula and requires local assessment.

Dosage formOral suspension
Reference batch200 mL
Monograph version4.0
Source packagev4

Source formula

IngredientSource quantity
Amiodarone 200 mg tablets5 δισκία / tablets
Sodium bicarbonate 50 mg/mL solution, to buffer vehicleq.s. pH 6.5 ± 0.5
Ora-Blend, buffered as describedq.s. ad 200 mL

Quantities refer to the source batch. This website does not automatically scale formulas, assign doses or calculate BUD.

Description

Documented in source

Opaque suspension.

References: [1]

Use and action

Documented in source

Antiarrhythmic requiring substantial monitoring and interaction assessment.
Active-drug context from another product’s labelling; it does not establish stability or dosing of this compounded preparation.

References: [2]

Specifications

Documented in source

Buffered vehicle: pH 6.5 ± 0.5. Check pH and final appearance.

References: [1]

Light

Partial evidence

For the finished product the source specifies:
Tight, light-resistant container. Refrigerate; the stated 90 days applies under refrigeration.

References: [1]

Air

Not established

No specific information is established by the consulted sources. Complete this before local approval where critical to this preparation.

References: [1]

Water and solubility

Not established

No specific information is established by the consulted sources. Complete this before local approval where critical to this preparation.

References: [1]

Humidity

Partial evidence

Protect sodium bicarbonate from moisture.

References: [3]

Temperature

Partial evidence

Heating sodium bicarbonate can cause conversion to sodium carbonate, in solid material or solution.

References: [3]

pH and related incompatibilities

Partial evidence

Sodium bicarbonate reacts with acids, releasing CO2.
Specification of this preparation, not a demonstrated stability range:
Buffered vehicle: pH 6.5 ± 0.5. Check pH and final appearance.

References: [1] · [3]

Other incompatibilities

Not established

No specific information is established by the consulted sources. Complete this before local approval where critical to this preparation.

References: [1]

Ingredient-specific information

Documented in source

Adjust vehicle to pH 6.5 ± 0.5 with 50 mg/mL NaHCO3 to prevent clumping. The 3 g/60 mL prepares buffer stock; it is not necessarily all added.

References: [1]

Personal protective equipment

Partial evidence

Complete formula-specific PPE is not specified. Select gloves, eye protection and exposure controls using the exact materials’ SDS and the local risk assessment.
Supplementary AEMPS framework: clean long-sleeved laboratory clothing, hair covering and dedicated footwear/overshoes. Powder handling requires suitable eye/respiratory protection; change gloves with activity or damage. Select the exact type/material using SDS and risk assessment.

References: [1] · [4]

Risks and precautions

Partial evidence

A complete formula-specific hazard classification is not established. Assess potency, dust/aerosol, allergens, solvents, microbial risk and cross-contamination using the actual materials and process. Absence of a flag does not establish absence of hazard.

References: [1]

Compounding conditions

Partial evidence

Follow the addition sequence, temperatures and times stated under Preparation Procedure. The specific monograph is not a complete qualification of the local facility/equipment.

References: [1]

BUD rationale

Documented in source

Source period: 90 days. Local BUD remains to be assessed.
The source period applies to its exact composition, method and packaging. It is not this batch’s expiry date and cannot be transferred to another vehicle/strength. Calculate the actual date in the blank batch record.

References: [1]

Bases and dependencies

Partial evidence

No separate base is identified in the dependency register. Check any commercial vehicles/compound excipients listed in the formula.

References: [1]

Equipment

Editorial checklist

Indicative checklist derived from the method: Balance of suitable resolution, Containers and mixing tools compatible with the materials, Mortar and pestle. Selection/qualification is defined locally.

References: [1]

Preparation procedure

Documented in source

Prepare sodium bicarbonate 50 mg/mL (3 g, irrigation water to 60 mL). Buffer 200 mL Ora-Blend using portions of this stock. Triturate tablets, levigate and dilute geometrically with buffered vehicle to 200 mL. Let foam settle 10 minutes; recheck volume.

References: [1]

Observations

Documented in source

The 3 g/60 mL is a stock, not an instruction to add all of it. Source reports clumping without buffering.

References: [1]

Packaging

Documented in source

Tight light-resistant container.

References: [1]

Quality control

Documented in source

Visual examination and pH measurement. Before incorporation, the vehicle must be pH 6.5 ± 0.5. Record final-product pH as well.

References: [1]

Storage

Documented in source

Tight, light-resistant container. Refrigerate; the stated 90 days applies under refrigeration.

References: [1]

Dispensing and directions

Partial evidence

No additional special directions are established beyond the source route, storage and notes. Complete patient details, dose and directions from the prescription.

References: [1]

Labelling

editorial_specimen

Amiodarone 5 mg/mL oral suspension
Strength/variant: __________ Quantity: __________
Batch: __________ Prepared: __________ Use by: __________
Από του στόματος / Oral use
Dose/directions: __________
Storage: Tight, light-resistant container. Refrigerate; the stated 90 days applies under refrigeration.
Shake before use.

References: [1]

Sources and traceability

  1. Nationwide Children’s Hospital — Pharmacy Services, institutional compounding formula

    03/2025 · PDF pp. 1–2 · B2

    Review date reported in supplied metadata: 2026-09-10

  2. DailyMed / NLM: AMIODARONE HYDROCHLORIDE TABLET [REMEDYREPACK INC.]

    SPL published Aug 07, 2026 · Indications / warnings / pharmacology · C1 context only

    Review date reported in supplied metadata: 2026-09-10

  3. FN/2003/PA/005 BICARBONATO DE SODIO

    Διαθέσιμο κείμενο / Retrieved text · PDF pp. 1–2 · A1

    Review date reported in supplied metadata: 2026-09-10

  4. PN/L/PG/002/00 INDUMENTARIA

    Διαθέσιμο κείμενο / Retrieved text · PDF pp. 1–5 · A1

    Review date reported in supplied metadata: 2026-09-10

Provenance and reuse

This record comes from the supplied v4 collection. Primary-source rights and licences remain separate. No new comprehensive licence review has been performed for the earlier 239 records.

SHA-256 of the supplied PDF: 26198d2838fba77a71c73fa09fc04d005ece5fb0c3cb7dac7c776ecbe1c8d42c